You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming March 8, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Tricida, Inc. (Tricida or the Company) (NASDAQ: TCDA) securities between September 4, 2019 and October 28, 2020, inclusive (the Class Period). If you suffered a loss on your Tricida investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/tricida-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. Tricidas drug candidate, veverimer, is a polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The Company has completed a Phase 3, double-blind, placebo-controlled trial of veverimer in patients with CKD and metabolic acidosis. On September 4, 2019, Tricida announced that it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under the Accelerated Approval Program for approval of veverimer for the treatment of metabolic acidosis in patients with CKD. On July 15, 2020, Tricida announced that it had received a notice from the FDA identif[ying] deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. The Company stated that [t]he notification does not specify the deficiencies identified by the FDA. On this news, the Companys stock price fell $10.56, or 40.31%, to close at $15.64 per share on July 16, 2020, thereby injuring investors. Then, on October 29, 2020, following its End-of-Review Type A meeting with the FDA, Tricida announced that it now believes the FDA will also require evidence of veverimers effect on CKD progression from a near-term interim analysis of the VALOR-CKD trial for approval under the Accelerated Approval Program and that the FDA is unlikely to rely solely on serum bicarbonate data for determination of efficacy. Tricida also disclosed that it was significantly reducing its headcount from 152 to 59 people and will discuss its commitments with vendors and contract service providers to potentially provide additional financial flexibility. On this news, the Companys stock price fell $3.90, or 47.16%, to close at $4.37 per share on October 29, 2020, thereby injuring investors. The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Tricida's NDA for veverimer was materially deficient; (2) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. Follow us for updates on LinkedIn, Twitter, or Facebook. If you purchased or otherwise acquired Tricida securities during the Class Period, you may move the Court no later than March 8, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Answer: Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Tricida, Inc. (TCDA)